US · EVAX
Evaxion Biotech A/S
- Sector
- Healthcare · Biotechnology
- Headquarters
- Horsholm 2970
- Website
- evaxion-biotech.com
Price · as of 2024-12-31
$4.50
Market cap 19.96M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $821.80 | +18,182.54% |
| Intrinsic Value(DCF) | $0.75 | -83.31% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $363.00 | ||||
| 2021 | $137.00 | ||||
| 2022 | $52.50 | ||||
| 2023 | $15.50 | ||||
| 2024 | $1.88 | $821.80 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Evaxion Biotech A/S's (EVAX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $821.80
- Current price
- $4.50
- AI upside
- +18,182.54%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.75
-83.31% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EVAX | Evaxion Biotech A/S | $4.50 | 19.96M | +18,183% | -83% | — | — | -0.19 | -1.22 | 0.60 | -0.72 | — | -1.22 | 100.00% | -440.55% | -316.00% | 331.20% | -693.28% | -83.29% | -6.11 | -15.31 | 2.01 | 1.58 | -0.52 | -6975.00% | 448082.00% | -2721.00% | -641.54% | -2.96 | -654.36% | 0.00% | 0.00% | 11.80% | -0.48 | -0.55 | 2.11 | -16.41 |
| ANVS | Annovis Bio, Inc. | $2.68 | 52.73M | — | — | — | — | 0.00 | 2.28 | — | -0.40 | 0.00 | 2.28 | 0.00% | — | — | -3159092.37% | 361.97% | -203782.88% | 0.00 | -14.40 | 3.59 | 2.72 | 0.40 | 3215955.00% | — | 5468129.00% | -103292.61% | -5641.50 | 296879.29% | 0.00% | 0.00% | 22.63% | -0.40 | 0.00 | — | -16.26 |
| BCAB | BioAtla, Inc. | $0.25 | 14.5M | — | +725% | — | — | -0.24 | 1.17 | 1.52 | 0.43 | — | 1.17 | 91.59% | -672.21% | -634.33% | -164.30% | 204.59% | -81.10% | 0.06 | — | 3.52 | 3.37 | 0.66 | -4419.00% | — | -3091.00% | -429.27% | -4.95 | 199.04% | 0.00% | 0.00% | 0.00% | 0.43 | 0.44 | -2.86 | -16.32 |
| BTAI | BioXcel Therapeutics, Inc… | $1.67 | 36.52M | +9,886% | -19% | — | — | -0.14 | -0.09 | 3.77 | -1.85 | — | -0.09 | 5.43% | -2967.56% | -2630.14% | 79.67% | 333.28% | -106.39% | -1.11 | -4.44 | 1.68 | 1.35 | -1.66 | -7610.00% | 6420.00% | -5354.00% | -843.12% | -3.24 | 356.98% | 0.00% | 0.00% | 0.00% | -1.21 | -1.13 | 36.03 | -28.96 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| GBIO | Generation Bio Co. | $5.34 | 35.98M | +46% | -60% | — | — | -0.27 | 0.41 | 1.78 | 0.76 | -40.69 | 0.41 | 100.00% | -715.82% | -661.91% | -91.02% | -912.79% | -43.46% | 1.09 | — | 5.50 | 5.33 | -0.23 | 66.00% | 23692.00% | 5125.00% | -256.40% | -2.53 | -583.12% | 0.00% | 0.00% | 39.99% | 0.39 | 0.62 | -2.82 | -5.24 |
| MURA | Mural Oncology plc | $2.04 | 35.38M | — | — | — | — | -0.48 | 0.44 | — | 0.60 | — | 0.44 | 0.00% | — | — | -63.57% | -2282.87% | -54.55% | 0.06 | — | 5.84 | 5.51 | 0.86 | -3902.00% | — | -3493.00% | -209.58% | -4.91 | -2123.95% | 0.00% | 0.00% | 0.00% | 0.54 | 0.58 | — | -1.84 |
| PYPD | PolyPid Ltd. | $4.25 | 43.31M | — | — | — | — | -2.08 | 6.47 | — | -1.91 | — | 6.47 | 0.00% | — | — | -366.29% | -2641.59% | -143.79% | 0.25 | -48.13 | 1.97 | 1.67 | 0.11 | -5743.00% | — | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -1.84 | — | — | -19.64 |
| RVPH | Reviva Pharmaceuticals Ho… | $0.21 | 14.64M | — | — | — | — | -1.27 | 46.91 | — | -0.84 | — | 46.91 | 0.00% | — | — | -916.17% | 206.33% | -152.63% | 0.56 | -1665.07 | 1.01 | 0.92 | 0.44 | -4545.00% | — | 1843.00% | -88.00% | -2.30 | 224.72% | 0.00% | 0.00% | 0.00% | -0.82 | -0.75 | — | -19.83 |
| SABS | SAB Biotherapeutics, Inc. | $4.10 | 39.19M | +213% | -84% | — | +2,692% | -0.44 | 0.58 | 11.35 | 0.04 | — | 0.58 | -262.41% | -3244.87% | -2579.03% | -81.92% | -519.55% | -53.23% | 0.18 | -134.77 | 2.98 | 2.61 | 0.15 | -5183.00% | -4094.00% | 3679.00% | -230.79% | -4.30 | -419.29% | 0.00% | 0.00% | 0.00% | 0.03 | 0.03 | -0.82 | -6.18 |
| VERU | Veru Inc. | $2.58 | 41.41M | +876% | — | — | — | -1.60 | 1.99 | — | -0.60 | — | 3.18 | 0.00% | — | — | -89.74% | -202.93% | -50.36% | 0.17 | — | 2.43 | 2.35 | 0.36 | -6179.00% | -10000.00% | 3756.00% | -82.38% | -3.86 | -246.33% | 0.00% | 0.00% | 4.46% | -0.86 | -0.71 | — | -15.28 |
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
- CEO
- Andreas Holm Mattsson
- Employees
- 46
- Beta
- 0.29
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.75 ÷ $4.50) − 1 = -83.31% (DCF, example).